Connect
MJA
MJA

Severe asthma: implementing game-changing science

Peter G Gibson
Med J Aust 2018; 209 (2): 66-67. || doi: 10.5694/mja18.00477
Published online: 16 July 2018

New assessment and treatment opportunities for people with severe asthma promise better outcomes

“It’s been a long time coming, but I feel great now.” “I feel like I’ve got my life back.” These are statements made by patients with severe asthma who have had positive responses to targeted monoclonal antibody therapy for asthma. Both patients have severe refractory eosinophilic asthma and have experienced many years of persistent symptoms despite daily maintenance prednisone. On monoclonal antibody therapy, they achieved complete symptom control and significant prednisone reduction.

  • Peter G Gibson

  • John Hunter Hospital, Newcastle, NSW


Competing interests:

I have received honoraria for the delivery of independent medical education and grants from GlaxoSmithKline, AstraZeneca and Novartis. I am also a member of the MJA Editorial Advisory Group.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.